Camber Capital Management as of March 31, 2018
Portfolio Holdings for Camber Capital Management
Camber Capital Management holds 32 positions in its portfolio as reported in the March 2018 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
---|---|---|---|---|---|
Shire | 8.1 | $164M | 1.1M | 149.39 | |
Nektar Therapeutics (NKTR) | 7.8 | $159M | 1.5M | 106.26 | |
Allergan | 7.0 | $143M | 850k | 168.29 | |
Biogen Idec (BIIB) | 6.9 | $141M | 515k | 273.82 | |
Hca Holdings (HCA) | 6.0 | $121M | 1.3M | 97.00 | |
Envision Healthcare | 5.4 | $110M | 2.9M | 38.43 | |
Tenet Healthcare Corporation (THC) | 5.1 | $103M | 4.3M | 24.25 | |
Tesaro | 4.8 | $99M | 1.7M | 57.14 | |
Universal Health Services (UHS) | 4.5 | $92M | 780k | 118.41 | |
Bristol Myers Squibb (BMY) | 3.9 | $79M | 1.3M | 63.25 | |
Genomic Health | 3.8 | $77M | 2.5M | 31.29 | |
Medicines Company | 3.2 | $66M | 2.0M | 32.94 | |
Atara Biotherapeutics | 3.1 | $63M | 1.6M | 39.00 | |
NuVasive | 3.1 | $63M | 1.2M | 52.21 | |
GlaxoSmithKline | 2.9 | $59M | 1.5M | 39.07 | |
Global Blood Therapeutics In | 2.9 | $58M | 1.2M | 48.30 | |
AMAG Pharmaceuticals | 2.6 | $53M | 2.7M | 20.15 | |
Mylan Nv | 2.5 | $52M | 1.3M | 41.17 | |
Myriad Genetics (MYGN) | 2.2 | $44M | 1.5M | 29.55 | |
Brookdale Senior Living (BKD) | 2.1 | $44M | 6.5M | 6.71 | |
Clovis Oncology | 2.1 | $44M | 825k | 52.80 | |
Endologix | 1.9 | $39M | 9.3M | 4.23 | |
Perrigo Company (PRGO) | 1.6 | $33M | 400k | 83.34 | |
Cardiovascular Systems | 1.3 | $27M | 1.2M | 21.93 | |
K2m Group Holdings | 1.3 | $26M | 1.3M | 18.95 | |
Valeant Pharmaceuticals Int | 1.2 | $24M | 1.5M | 15.92 | |
Wright Medical Group Nv | 0.8 | $16M | 815k | 19.84 | |
Endo International | 0.7 | $15M | 2.5M | 5.94 | |
Dicerna Pharmaceuticals | 0.5 | $9.6M | 1.0M | 9.56 | |
Prothena (PRTA) | 0.5 | $9.2M | 250k | 36.71 | |
Momenta Pharmaceuticals | 0.1 | $2.5M | 135k | 18.15 | |
Surgery Partners (SGRY) | 0.1 | $2.3M | 135k | 17.15 |